Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GWJ-A-10
- Development stage
- Discontinued
- Lead developer
- University of Georgia
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
GWJ-A-10 is a lysophosphatidylcholine (LPC) analogue that was developed as a negative control compound for the study of autotaxin (ATX) inhibitors. It is structurally related to active irreversible inhibitors like CVS-16 (10b) but lacks the critical vinyl sulfone moiety required for covalent inactivation of the autotaxin enzyme. In preclinical research focused on melanoma, GWJ-A-10 demonstrated minimal impact on cell viability and failed to inhibit autotaxin activity or prevent angiogenesis, thereby serving as a structural control to validate the mechanism of action of electrophilic LPC analogues in targeting malignant progression.
Beyond the preview
Go deeper on GWJ-A-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GWJ-A-10.